Satellos Bioscience to Present at Bloom Burton Conference

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026.

Rhea-AI Filing Summary

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. Co-founder and CEO Frank Gleeson will give a presentation on April 21 at 11:30 a.m., with a live webcast and replay available via the Investors section of the company’s website.

The company is developing SAT-3247, an orally administered small molecule therapy aimed at restoring muscle repair and regeneration. SAT-3247 is being studied as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase II trials, BASECAMP in pediatric patients and TRAILHEAD in adults.

Key Figures

Conference dates: April 21-22, 2026 Presentation time: 11:30 a.m. Clinical trial phase count: Two Phase II clinical trials

3 metrics

Conference dates April 21-22, 2026 Bloom Burton & Co. Healthcare Investor Conference schedule

Presentation time 11:30 a.m. Frank Gleeson conference presentation on April 21

Clinical trial phase count Two Phase II clinical trials BASECAMP in pediatrics and TRAILHEAD in adults for SAT-3247

Key Terms

clinical-stage, Phase II clinical trials, disease-modifying treatment, dystrophin-independent, +1 more

5 terms

clinical-stage financial

"a clinical-stage biotechnology company developing life-improving medicines"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

Phase II clinical trials medical

"in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults"

Phase II clinical trials are studies that evaluate whether an experimental drug or therapy actually works and is reasonably safe in a larger group of patients after initial safety checks. Investors care because results provide the first meaningful evidence of effectiveness and side effects—like a prototype tested with real users—informing whether a program is likely to advance, shaping a drug’s future value and the company’s funding and partnership prospects.

disease-modifying treatment medical

"being evaluated as a potential disease-modifying treatment, initially for DMD"

A disease-modifying treatment is a therapy that changes the underlying course of a chronic illness rather than only easing symptoms, like repairing a leak in a roof instead of just mopping up the water. For investors it matters because such treatments can sustain patient benefits over time, command higher prices, shift long-term healthcare costs and create lasting market advantages or risks depending on how widely and quickly they are adopted and reimbursed.

dystrophin-independent medical

"By addressing the loss in a dystrophin-independent manner, SAT-3247 may re-establish"

AAK1 medical

"SAT-3247 targets AAK1, a key protein that Satellos has identified"

AAK1 is a human gene that makes a protein acting like a traffic controller inside cells, helping move and sort molecules into and out of the cell. Investors care because drugs that block or modify AAK1 can change how cells handle infections or neurological signals, so evidence that a therapy affects AAK1 can influence the value of biotech pipelines, clinical trial prospects, and future regulatory or commercial outcomes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Satellos Bioscience Inc. (MSLE) announce in this 6-K filing?

Satellos announced its participation in the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026. CEO Frank Gleeson will present on April 21 at 11:30 a.m., with a live webcast and replay available through the company’s investor relations website.

When and where will Satellos (MSLE) present at the Bloom Burton healthcare conference?

Satellos will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, at the Metro Toronto Convention Centre. CEO Frank Gleeson’s presentation is scheduled for April 21 at 11:30 a.m., with online access via webcast for remote viewers.

What is Satellos’ lead drug candidate SAT-3247 mentioned in the filing?

SAT-3247 is Satellos’ orally administered small molecule therapy designed to restore natural muscle repair and regeneration. It targets the AAK1 protein and is being evaluated as a potential disease-modifying treatment for Duchenne muscular dystrophy in ongoing Phase II clinical trials.

Which clinical trials are evaluating SAT-3247 for Duchenne muscular dystrophy?

SAT-3247 is being evaluated in two Phase II clinical trials: BASECAMP in pediatric patients and TRAILHEAD in adults. Both studies assess whether targeting AAK1 can help restore muscle repair and regeneration in Duchenne muscular dystrophy, potentially offering disease-modifying benefits.

How can investors access Satellos’ Bloom Burton conference presentation?

Investors can access the presentation via a live webcast hosted on the Events and Presentations page in Satellos’ Investors section. A replay will also be available after the session, allowing viewers to watch the April 21, 11:30 a.m. talk at a later time.

What therapeutic focus does Satellos Bioscience (MSLE) highlight in this update?

Satellos highlights its focus on restoring natural muscle repair and regeneration in degenerative muscle diseases. The company emphasizes SAT-3247, which targets AAK1 and is being developed as a dystrophin-independent, potentially disease-modifying treatment for Duchenne muscular dystrophy across pediatric and adult populations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 07:00 AM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-43107

SATELLOS BIOSCIENCE INC.
(Translation of registrant's name into English)

Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800
Toronto, Ontario, ON M5J 2J3
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Exhibit		Description
99.1		Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		SATELLOS BIOSCIENCE INC.
		(Registrant)
Date: April 9, 2026		/s/ Elizabeth Williams, CPA, CA
		Elizabeth Williams, CPA, CA
		Chief Financial Officer

EXHIBIT 99.1

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Tuesday, April 21
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre

The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website, and a replay will be available following the presentation.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to address deficits in muscle repair and regeneration. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental stem cell driven process that is disrupted in DMD and other degenerative conditions. By addressing the loss in a dystrophin-independent manner, SAT-3247 may re-establish the biochemical signals needed to support muscle regeneration, with potential broad applicability as either a stand-alone or adjunctive therapy. Satellos has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.

CONTACTS

Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 3.6 KB